Clinical Trial Detail

NCT ID NCT02129075
Title CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301in Treating Patients With Stage IIB-IV Melanoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

melanoma

Therapies

NeoVax melanoma vaccine

CDX-301

Rasdegafusp alfa

Age Groups: adult

No variant requirements are available.